

KFIN/CERT13(3)/MAR/2024

Date : April 2, 2024

Mr. Ajay Nadkarni  
M/s. GlaxoSmithKline Pharmaceuticals Limited  
Dr. Annie Besant Road  
Worli, Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended March 31, 2024.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended March 31, 2024.

Description of Complaint	Opening Balance as on 01.01.2024	Received during the Period 01.01.2024 to 31.03.2024	Attended/Resolved during the Period 01.01.2024 to 31.03.2024	Pending as on 31.03.2024
Non-receipt of Dividend	NIL	08	08	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of shares	NIL	04	04	NIL
SEBI	NIL	02	02	NIL
Stock Exchange	NIL	03	03	NIL
Total	NIL	17	17	NIL

This is for your information and record.

Thanking you,

Yours faithfully  
For KFin Technologies Limited



Rajitha Cholleti  
Dy. Vice President